Life Sciences
More
-
NEW YORK-- Shares of Navidea Biopharmaceuticals Inc. rose Thursday after the company reported favorable new clinical trial results for its imaging agent Lymphoseek. The Food and Drug Administration approved Lymphoseek March 13 to help doctors locate lymph nodes in patients with breast cancer and skin cancer.
-
*Experts in daily talks on risks posed by new China virus. LONDON, April 4- Experts from around the world are in daily talks about the threat posed by a deadly new strain of bird flu in China, including discussions on if and when to start making a vaccine.
-
*Under new CEO, Sarepta focused on Duchenne muscular dystrophy drug. *Analysts expect company to relay FDA feedback in April. April 2- After three decades without bringing a drug to market, Sarepta Therapeutics Inc stands on the verge of a breakthrough with its treatment for a crippling genetic disorder that affects one in every 3,500 newborn boys.
-
LONDON, March 27- British scientists have developed a new vaccine against foot-and-mouth disease that is safer and easier to manufacture, an advance they believe should greatly increase production capacity and reduce costs. "It spreads like wild fire," said David Stuart, a professor of biology at the University of Oxford, who led the research.
-
AUSTIN, Texas-- State leaders on Tuesday announced the construction of a $91 million vaccine manufacturing center at Texas A&M University that they said will create thousands of jobs while protecting the country against future biological threats and influenza pandemics.
-
*Announces FDA acceptance of biologics license application for investigational. grass pollen allergy immunotherapy tablet. *Source text for Eikon* Further company coverage.
-
*Company to halt drug development for soft tissue sarcoma. March 26- Ziopharm Oncology Inc will stop developing its drug to treat soft tissue sarcoma after it failed to improve patients' survival without the cancer worsening, wiping out nearly two-thirds of its market value.
-
March 25- ARCA Biopharma Inc:. *Files to make offering of its common stock and warrants to purchase shares of. up to $20 million- SEC filing.
-
CAMBRIDGE, Mass.-- Idenix Pharmaceuticals Inc. shares sank Monday after the U.S. The biopharmaceutical company said an appeals board decided that Idenix's patent application for compounds used to treat hepatitis C was filed after Gilead Pharmasset LLC's application.
-
**APOLLO GROUP, $19.40, up 14 pct. Apollo Group Inc, owner of the University of Phoenix, said it will increase its focus on non-degree courses in an attempt to diversify its product offerings and attract more students, after reporting a fourth straight quarter of enrollment declines. **EQUAL ENERGY LTD, $3.92, up 12 pct.
-
Apollo Group Inc, owner of the University of Phoenix, said it will increase its focus on non-degree courses in an attempt to diversify its product offerings and attract more students, after reporting a fourth straight quarter of enrollment declines. **EQUAL ENERGY LTD, $3.92, up 12 pct.
-
"GSK and the FDA are actively working together to complete the review in a timely manner," it added. There is growing evidence of a link between GSK's earlier H1N1 flu vaccine, Pandemrix, and an increase in narcolepsy cases among children who received it in Europe- a fact which has raised questions as to whether the FDA should approve the similar H5N1 product.
-
Apollo Group Inc, owner of the University of Phoenix, said it will increase its focus on non-degree courses in an attempt to diversify its product offerings and attract more students, after reporting a fourth straight quarter of enrollment declines. **EQUAL ENERGY LTD, $3.89, up 11 pct.
-
Banking stocks rose after a deal between Cyprus and heads of the European Union, the European Central Bank and the International Monetary Fund will spare the Mediterranean island a financial meltdown by winding down the largely state-owned Popular Bank of Cyprus and shifting deposits below 100,000 euros to the Bank of Cyprus to create a "good bank".
-
*Gets complete response from FDA for candidate pandemic H5N1 adjuvanted.
-
LONDON, March 25- U.S. regulators have delayed approval of an H5N1 bird flu vaccine from GlaxoSmithKline, designed to be used in a pandemic. The vaccine had been backed by an expert panel in November but GSK said on Monday the Food and Drug Administration had informed it that additional review time was needed before approval.
-
March 25- Array Biopharma Inc:. *Piper Jaffray raises to overweight from neutral; target price to $7 from $4. Reuters Station users, click. 1568.
-
March 25- Galena Biopharma Inc:. *Roth Capital raises price target to $7 from $5; rating buy. Reuters Station users, click. 1568.
-
March 25- Galena Biopharma Inc:. Reuters Station users, click. 1568. Reuters Station users, click. 4899.
-
The antidote, Botulism Antitoxin Heptavalent, is made by Winnipeg, Canada- based Cangene Corp, and was developed under a $427 million contract with the U.S. Department of Health and Human Services that makes the company eligible for a supplementary payment upon the treatment's FDA approval.